Temferon is under clinical development by Genenta Science and currently in Phase II for Supratentorial Glioma. According to GlobalData, Phase II drugs for Supratentorial Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Temferon LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
It was also under development for the treatment of relapsed multi myeloma.
Genenta Science overview
Genenta Science, formerly Genenta Science, is a biotechnology company that discovers and develops cell and gene therapies for cancer. It investigates Temferon, a lenti-virus based hematopoietic stem progenitor cell immuno therapy for the treatment of glioblastoma multiforme, solid and hematologic tumors. Its drug candidate enables controlled and targeted interferon-a expression within cancers. Genenta Science utilizes its proprietary TEMs (Tie2 expressing monocytes) platform that centers on a transgene expression control vector providing dual control at the transcriptional and post-transcriptional level. The company is a spin-out from the San Raffaele Hospital. Geneta Science is headquartered in Milan, Lombardy, Italy.
For a complete picture of Temferon’s drug-specific PTSR and LoA scores, buy the report here.